PHAR Rasio cepet Pharming Group N.V.

Pharming Group N.V. (PHAR) business risks are driven by its reliance on a single product and the threat posed by gene therapy. However, the brand maintains the trust of medical professionals due to its high-quality treatments for angioedema. The company is currently scaling its portfolio and launching new drugs while maintaining a steady cash flow. The quick ratio stands at 2.64. This pharmaceutical company's current share price chart is provided below.

This indicator assesses the ability of Pharming Group N.V. (PHAR) to instantaneously settle short-term debts using cash and accounts receivable, completely excluding slow-moving inventories. By analyzing the quick ratio trend, an investor can gauge the financial resilience of Pharming Group N.V., which is critical given the company's reliance on external CMO plants and the necessity of securing long-term forward contracts for drug purification.